Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the preclinical studies and ongoing clinical trials of CAR T cells in autoimmune disorders, highlighting future opportunities and challenges.
- Jérôme Avouac
- Adi Barzel
- Derya Unutmaz